User250673

Syneron Medical's Superb Q2 Treatment

CYNO qtly rev growth 30.10% vs ELOS 1.90%. CYNO ROA 10.35% vs ELOS 6.58%. CYNO ROE 16.4% vs ELOS 13.4%. Don't get me wrong, I own both and both are leaders in the industry, but CYNO is clearly outperforming CUTR, CLZR, ELOS, PMTI etc. ELOS hdqt in Israel is a definite risk and their share price is going to stay depressed until there's more stability in the Mid-East no matter how much they sell overseas. ELOS deferred LT liabilities far outweight CYNO minimal debt, not that it changes anything.

Syneron Medical's Superb Q2 Treatment

HELLOOOOOOO...... CUTR? CLZR? How in the world can you talk about no debt successfull companies in this market without even mentioning the market leader? CYNOSURE